Conference Coverage (Blood Safety)

Inactivation Compound Compares Favorably to Methane Blue

Published in Blood Weekly, May 12th, 1997

A phenothiazine derivative, compound 4-91, shows potential use for inactivating viruses in red cell (RBC) components.

Novel phenothiazine compounds have been developed to photoinactivate viruses in RBC suspensions, noted Dr. Stephen J. Wagner, Scientist, Product Development Department, Holland Laboratory, American Red Cross, Rockville, Maryland, at the Blood Safety & Screening Conference, sponsored by Cambridge Healthtech Institute, held April 14-16, 1997, in McLean, Virginia.

In screening compounds for virus inactivation and to detect alteration of in vitro RBC properties, Red Cross researchers identified compound 4-91, which had desirable virucidal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-05-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry